Clinical Immunology and Immunopathology
ReviewThe role of α1-antitrypsin deficiency in the pathogenesis of immune disorders
References (143)
- et al.
Biochim. Biophys. Acta
(1973) - et al.
Clin. Chim. Acta
(1967) - et al.
Fertil. Steril.
(1976) - et al.
Fertil. Steril.
(1968) - et al.
J. Allergy Clin. Immunol.
(1976) - et al.
Lancet
(1977) - et al.
Lancet
(1979) - et al.
Lancet
(1977) - et al.
Lancet
(1977) - et al.
Lancet
(1978)
Amer. J. Med.
J. Biol. Chem.
Clin. Immunol. Immunopathol.
Lancet
Biochem. Biophys. Res. Commun.
Adv. Immunol.
Int. J. Immunopharmacol.
Biochem. Biophys. Res. Commun.
Scand. J. Clin. Lab. Invest.
Hum. Genet.
Protides Biol. Fluids
Hum. Hered.
Scand. J. Clin. Lab. Invest.
Humangenetik
Eur. J. Biochem.
Hum. Hered.
Clin. Genet.
J. Clin. Invest.
Ann. Hum. Genet.
Cytogenet. Cell Genet.
Nature (London)
Arch. Environ. Health
Mt. Sinai J. Med.
Acta Med. Scand.
N. Engl. J. Med.
N. Engl. J. Med.
Acta Allergol.
Trans. Assoc. Amer. Phys.
J. Allergy Clin. Immunol.
Ann. Allergy
Clin. Allergy
J. Amer. Med. Assoc.
Chest
Arthritis Rheum.
Lancet
Clin. Genet.
Aust. N.Z. J. Med.
J. Clin. Invest.
Cited by (110)
Alpha-1 antitrypsin suppresses macrophage activation and promotes islet graft survival after intrahepatic islet transplantation
2021, American Journal of TransplantationBiomarker-guided preemption of steroid-refractory graft-versus-host disease with a-1-antitrypsin
2020, Blood AdvancesCitation Excerpt :The ideal agent for a preemptive treatment strategy, especially one administered early after HCT, would offer protection with minimal toxicity. α-1-Antitrypsin (AAT) is a serine protease inhibitor with anti-apoptotic, anti-inflammatory, and immunomodulatory properties.11-14 It is approved by the US Food and Drug Administration for the treatment of AAT deficiency and has been widely administered, with few side effects.
α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: A role for mitochondrial bioenergetics
2014, BloodCitation Excerpt :These cytokines, including tumor necrosis factor α (TNFα), interleukin 1β (IL-1β), and interferon γ (IFN-γ), promote T-helper 1 (Th-1) cell differentiation and enhance their proliferation and reactivity against host tissues. The administration of α-1-antitrypsin (AAT), used therapeutically in patients with genetically determined AAT deficiency-related emphysema,6 profoundly alters cytokine profiles and has been shown to suppress GVHD.7-9 AAT is a serine protease inhibitor, which in addition to changes in cytokine profiles, also affects the redox status of cells and cell-mediated immunity, among other functions.6,10-15
Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels
2023, Journal of Proteome Research